Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Nano-sized Drug Carriers and Key Factors for Lymphatic Delivery

  • Choi, Ji-Hoon (College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University) ;
  • Lee, Yong-Bok (College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University)
  • Received : 2010.09.09
  • Accepted : 2010.10.06
  • Published : 2010.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Specific diseases like cancer and acquired immune deficiency syndrome (AIDS) occur at various organs including lymphatics and spread through lymphatic system. Thus, if therapeutic agents for such diseases are more distributed or targeted to lymphatic system, we can obtain several advantages like reduction of systemic side effect and increase of efficacy. For these reasons, much interest has been focused on the nature of lymphatics and a lot of studies for lymphatic delivery of drugs have been carried out. Because lymphatics consist of single layer endothelium and have high permeability compared with blood capillaries, especially, the studies using nano-sized carriers have been performed. Polymeric nano-particle, liposome, and lipid-based vehicle have been adopted for lymphatic delivery as carriers. According to the administration route and the kind of carrier, the extent of lymphatic delivery efficiency of nano-sized carriers has been changed and influenced by several factors such as size, charge, hydrophobicity and surface feature of carrier. In this review, we summarized the key factors which affect lymphatic uptake and the major features of carriers for achieving the lymphatic delivery. Lymphatic delivery of drug using nano-sized carriers has many fold improved ability of lymphatic delivery compared with that of conventional dosage forms, but it has not shown whole lymph selectivity yet. Even though nano-sized carriers still have the potential and worth to study as lymphatic drug delivery technology as before, full understanding of delivery mechanism and influencing factors, and setting of pharmacokinetic model are required for more ideal lymphatic delivery of drug.

Keywords

References

  1. Allen, T., Hansen, C., Guo, L., 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochimica et Biophysica Acta (BBA)-Biomembranes 1150, 9-16. https://doi.org/10.1016/0005-2736(93)90115-G
  2. Allen, T., Moase, E., 1996. Therapeutic opportunities for targeted liposomal drug delivery. Advanced drug delivery reviews 21, 117-133. https://doi.org/10.1016/S0169-409X(96)00402-4
  3. Cavanagh, L.L., Von Andrian, U.H., 2002. Travellers in many guises: the origins and destinations of dendritic cells. Immunol Cell Biol 80, 448-462. https://doi.org/10.1046/j.1440-1711.2002.01119.x
  4. Chambers, A.F., Groom, A.C., Macdonald, I.C., 2002. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572. https://doi.org/10.1038/nrc865
  5. Charman, W., Porter, C., 1996. Lipophilic prodrugs designed for intestinal lymphatic transport. Advanced drug delivery reviews 19, 149-169. https://doi.org/10.1016/0169-409X(95)00105-G
  6. Charman, W., Stella, V., 1986. Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. International Journal of Pharmaceutics 33, 165-172. https://doi.org/10.1016/0378-5173(86)90050-5
  7. Feng, L., Zhang, L., Liu, M., Yan, Z., Wang, C., Gu, B., Liu, Y., Wei, G., Zhong, G., Lu, W., 2010. Roles of dextrans on improving lymphatic drainage for liposomal drug delivery system. J Drug Target 18, 168-178. https://doi.org/10.3109/10611860903318126
  8. Garg, M., Jain, N.K., 2006. Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes. J Drug Target 14, 1-11. https://doi.org/10.1080/10611860500525370
  9. Gershkovich, P., Hoffman, A., 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 26, 394-404. https://doi.org/10.1016/j.ejps.2005.07.011
  10. Gursoy, R.N., Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58, 173-182. https://doi.org/10.1016/j.biopha.2004.02.001
  11. Hawley, A.E., Illum, L., Davis, S.S., 1997. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res 14, 657-661. https://doi.org/10.1023/A:1012117531448
  12. Immordino, M.L., Dosio, F., Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1, 297-315. https://doi.org/10.2217/17435889.1.3.297
  13. Jurisic, G., Detmar, M., 2009. Lymphatic endothelium in health and disease. Cell Tissue Res 335, 97-108. https://doi.org/10.1007/s00441-008-0644-2
  14. Karajgi, J.S., Vyas, S.P., 1994. A lymphotropic colloidal carrier system for diethylcarbamazine: preparation and performance evaluation. J Microencapsul 11, 539-545. https://doi.org/10.3109/02652049409034992
  15. Kaur, C.D., Nahar, M., Jain, N.K., 2008. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target 16, 798-805. https://doi.org/10.1080/10611860802475688
  16. Kim, C.K., Han, J.H., 1995. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul 12, 437-446. https://doi.org/10.3109/02652049509087256
  17. Kohli, K., Chopra, S., Dhar, D., Arora, S., Khar, R.K., 2010. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today
  18. Ling, S.S., Magosso, E., Khan, N.A., Yuen, K.H., Barker, S.A., 2006. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm 32, 335-345. https://doi.org/10.1080/03639040500519102
  19. Luo, G., Yu, X., Jin, C., Yang, F., Fu, D., Long, J., Xu, J., Zhan, C., and Lu, W., 2010. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 385, 150-156. https://doi.org/10.1016/j.ijpharm.2009.10.014
  20. Muller, C.D., Schuber, F., 1989. Neo-mannosylated liposomes: synthesis and interaction with mouse Kupffer cells and resident peritoneal macrophages. Biochim Biophys Acta 986, 97-105. https://doi.org/10.1016/0005-2736(89)90277-0
  21. Nankervis, R., Davis, S., Day, N., Shaw, P., 1996. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. International Journal of Pharmaceutics 130, 57-64. https://doi.org/10.1016/0378-5173(95)04265-2
  22. O'driscoll, C.M., 2002. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 15, 405-415. https://doi.org/10.1016/S0928-0987(02)00051-9
  23. Oussoren, C., Storm, G., 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50, 143-156. https://doi.org/10.1016/S0169-409X(01)00154-5
  24. Oussoren, C., Zuidema, J., Crommelin, D.J., Storm, G., 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta 1328, 261-272. https://doi.org/10.1016/S0005-2736(97)00122-3
  25. Paliwal, R., Paliwal, S. R., Mishra, N., Mehta, A., Vyas, S.P., 2009. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 380, 181-188. https://doi.org/10.1016/j.ijpharm.2009.06.026
  26. Parker, R. J., Hartman, K.D., Sieber, S.M., 1981. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res 41, 1311-1317.
  27. Patel, H.M., Boodle, K.M., Vaughan-Jones, R., 1984. Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes. Biochim Biophys Acta 801, 76-86. https://doi.org/10.1016/0304-4165(84)90214-9
  28. Pepper, M.S., Skobe, M., 2003. Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol 163, 209-213. https://doi.org/10.1083/jcb.200308082
  29. Rao, D.A., Forrest, M.L., Alani, A.W., Kwon, G.S., Robinson, J. R., 2010. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 99, 2018-2031. https://doi.org/10.1002/jps.21970
  30. Senior, J.H., 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3, 123-193.
  31. Shin, S.B., Cho, H.Y., Kim, D.D., Choi, H.G., Lee, Y.B., 2010. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74, 164-171. https://doi.org/10.1016/j.ejpb.2009.08.006
  32. Singh, R., Lillard, J.W., Jr., 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86, 215-223. https://doi.org/10.1016/j.yexmp.2008.12.004
  33. Supersaxo, A., Hein, W.R., Steffen, H., 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7, 167-169. https://doi.org/10.1023/A:1015880819328
  34. Swartz, M.A., 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50, 3-20. https://doi.org/10.1016/S0169-409X(01)00150-8
  35. Takakura, Y., Atsumi, R., Hashida, M., Sezaki, H., 1987. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. International Journal of Pharmaceutics 37, 145-154. https://doi.org/10.1016/0378-5173(87)90019-6
  36. Takakura, Y., Matsumoto, S., Hashida, M., Sezaki, H., 1984. Enhanced lymphatic delivery of mitomycin C conjugated with dextran. Cancer Res 44, 2505-2510.
  37. Tanis, P.J., Nieweg, O.E., Valdes Olmos, R.A., Kroon, B.B., 2001. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 192, 399-409. https://doi.org/10.1016/S1072-7515(00)00776-6
  38. Trevaskis, N.L., Charman, W.N., Porter, C.J., 2008. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60, 702-716. https://doi.org/10.1016/j.addr.2007.09.007
  39. Trevaskis, N.L., Porter, C.J., Charman, W.N., 2006. The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport. J Pharmacol Exp Ther 316, 881-891.
  40. Tumer, A., Kirby, C., Senior, J., Gregoriadis, G., 1983. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim Biophys Acta 760, 119-125. https://doi.org/10.1016/0304-4165(83)90132-0
  41. Xie, Y., Bagby, T.R., Cohen, M.S., Forrest, M.L., 2009. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin Drug Deliv 6, 785-792. https://doi.org/10.1517/17425240903085128

Cited by

  1. Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery vol.41, pp.8, 2018, https://doi.org/10.1007/s12272-018-1060-0